AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34637450 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (control group).
Number of subjects: 96
Study 32451005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gordon's functional health pattern model nursing care
Number of subjects: 120
Study 32451005 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 120
Study 34894266 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 39
Study 34894266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 32541143 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (TEM) 25 mg i.v. once a week
Number of subjects: 22
Study 32541143 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (SUN) 50 mg p.o. daily for 4 weeks on and 2 weeks off
Number of subjects: 22
Study 32541143 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 22
Study 32541143 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (TEM)
Number of subjects: 22
Study 36375173 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg duloxetine
Number of subjects: 78
Study 36375173 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg duloxetine
Number of subjects: 78
Study 36375173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 34082620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 11795
Study 34082620 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11795
Study 34082620 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia treatment (iron, erythropoiesis-stimulating agents, and/or red blood cell transfusion)
Number of subjects: 11795
Study 34082620 — intervention group
Group type: COMPARATOR
Intervention: No anemia treatment
Number of subjects: 11795
Study 33103322 — intervention group
Group type: COMPARATOR
Intervention: Novel treatments
Number of subjects: 134
Study 33440077 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir (oral and intravenous administration)
Number of subjects: 0
Study 32499026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable-polymer sirolimus-eluting stents (BP SES)
Number of subjects: 1334
Study 32499026 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stents (DP EES)
Number of subjects: 1334
Study 34391038 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy achievement condition (emphasis on social support and connection)
Number of subjects: 39
Study 34391038 — intervention group
Group type: COMPARATOR
Intervention: Standard motivation condition
Number of subjects: 39
Study 34391038 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy achievement condition
Number of subjects: 39
Study 33866430 — intervention group
Group type: EXPERIMENTAL
Intervention: MYL‐1402O
Number of subjects: 111
Study 33866430 — intervention group
Group type: COMPARATOR
Intervention: EU-reference bevacizumab
Number of subjects: 111
Study 33866430 — intervention group
Group type: COMPARATOR
Intervention: US-reference bevacizumab
Number of subjects: 111
Study 33866430 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 111
Study 33741803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 33741803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 32609313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily for 12 weeks
Number of subjects: 3623
Study 32609313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily for 52 weeks
Number of subjects: 3623
Study 32609313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily for 24 weeks
Number of subjects: 3623
Study 32609313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 3623
Study 35362109 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-based treatment recommendations
Number of subjects: 260
Study 35362109 — intervention group
Group type: COMPARATOR
Intervention: FFR-based treatment recommendations
Number of subjects: 260
Study 32961094 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis
Number of subjects: 147
Study 32961094 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-2013)
Number of subjects: 147
Study 33296982 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 2 mg twice a day
Number of subjects: 30
Study 33296982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33853157 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee distraction
Number of subjects: 0
Study 33853157 — intervention group
Group type: COMPARATOR
Intervention: High tibial osteotomy
Number of subjects: 0
Study 35182906 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory neuroscience-informed cognitive training
Number of subjects: 79
Study 35182906 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual neuroscience-informed cognitive training
Number of subjects: 79
Study 34302758 — intervention group
Group type: EXPERIMENTAL
Intervention: Itepekimab 300 mg administered as two subcutaneous injections every 2 weeks for 24-52 weeks
Number of subjects: 343
Study 34302758 — intervention group
Group type: EXPERIMENTAL
Intervention: Itepekimab in former smokers
Number of subjects: 343
Study 34302758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 32106835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention engagement and adherence
Number of subjects: 729
Study 32106835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 729
Study 34654026 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril and 0.8 mg folic acid
Number of subjects: 20688
Study 34654026 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril alone
Number of subjects: 20688
Study 34231962 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing interventions
Number of subjects: 106
Study 34231962 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing care (Control)
Number of subjects: 106
Study 35771495 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT-DH
Number of subjects: 114
Study 35771495 — intervention group
Group type: COMPARATOR
Intervention: MBT-IOP
Number of subjects: 114
Study 32654836 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media messages (visual based, quiz, text only)
Number of subjects: 928
Study 32654836 — intervention group
Group type: COMPARATOR
Intervention: No-message control
Number of subjects: 928
Study 32936085 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored transdiagnostic guided internet intervention for anxiety disorders (7-session intervention)
Number of subjects: 49
Study 35430997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/Caffeine combination (400/100 mg)
Number of subjects: 26
Study 35430997 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 26
Study 33504513 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel (600 mg, day 1; 150 mg, days 2-7; then 75 mg/day)
Number of subjects: 1599
Study 33504513 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (300 mg, day 1; then 75 mg/day)
Number of subjects: 1599
Study 33504513 — intervention group
Group type: COMPARATOR
Intervention: Patients with obstructive CAD (control group)
Number of subjects: 1599
Study 33504513 — intervention group
Group type: EXPERIMENTAL
Intervention: MINOCA patients
Number of subjects: 1599
Study 34302129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g l-arginine and 1.2 g aged garlic extract (AGE) daily for 6 weeks
Number of subjects: 1
Study 34302129 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study 33166759 — intervention group
Group type: EXPERIMENTAL
Intervention: Florfenicol resistance gene detection (floR)
Number of subjects: 30
Study 33166759 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum inhibitory concentration (MIC) determination for florfenicol
Number of subjects: 30
Study 33166759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial identification
Number of subjects: 30
Study 33166759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence analysis of floR
Number of subjects: 30
Study 35711483 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 60
Study 33154429 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR alert activation
Number of subjects: 8299
Study 33154429 — intervention group
Group type: COMPARATOR
Intervention: Control (no alert)
Number of subjects: 8299
Study 36364748 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (150,000 IU in vegetable oil 24 h before the run)
Number of subjects: 35
Study 36364748 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study 36364748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 33087061 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Care Planning (ACP) program
Number of subjects: 0
Study 33087061 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up and care (Control)
Number of subjects: 0
Study 34281958 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxalate quartile (≥59.7 µM)
Number of subjects: 1255
Study 33496884 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with Zn-Met 60 mg/kg (T3)
Number of subjects: 480
Study 33496884 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with Zn-Met 40 mg/kg (T2)
Number of subjects: 480
Study 33496884 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with Zn-Met 20 mg/kg (T1)
Number of subjects: 480
Study 33496884 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (control, 40 mg/kg)
Number of subjects: 480
Study 32356023 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg kg‐1)
Number of subjects: 18
Study 32323557 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (150,000 IU daily for 3 days before surgery)
Number of subjects: 70
Study 33632715 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study 32155773 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Sport Activity Program (ESA) with additional warm-up protocol for 14 weeks
Number of subjects: 672
Study 32155773 — intervention group
Group type: COMPARATOR
Intervention: Ordinary exercise activity (Control)
Number of subjects: 672
Study 34590235 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based extended-release naltrexone
Number of subjects: 116
Study 34590235 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 116
Study 33254239 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist supported self-management programme plus a verum thumb splint (SSM+S)
Number of subjects: 349
Study 33254239 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist supported self-management programme plus a placebo thumb splint (SSM+PS)
Number of subjects: 349
Study 33254239 — intervention group
Group type: COMPARATOR
Intervention: Therapist supported self-management programme (SSM)
Number of subjects: 349
Study 32173650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cy/GVAX plus degarelix
Number of subjects: 0
Study 32173650 — intervention group
Group type: COMPARATOR
Intervention: Degarelix alone
Number of subjects: 0
Study 36453001 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative therapy group sessions (8 weekly 2-hour sessions)
Number of subjects: 200
Study 36453001 — intervention group
Group type: COMPARATOR
Intervention: Current model of psychoeducational group (control)
Number of subjects: 200
Study 36453001 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative therapy
Number of subjects: 200
Study 32777055 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 365
Study 32777055 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 365
Study 35948454 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training plus proprioceptive neuromuscular facilitation (PNF) therapy
Number of subjects: 42
Study 35948454 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 42
Study 35287479 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall Arrest Strategy Training (FAST)
Number of subjects: 40
Study 35287479 — intervention group
Group type: COMPARATOR
Intervention: Standard fall prevention exercises
Number of subjects: 40
Study 35287479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FAST and Standard
Number of subjects: 40
Study 35191898 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 33
Study 35191898 — intervention group
Group type: EXPERIMENTAL
Intervention: DEXA (Dual-energy x-ray absorptiometry)
Number of subjects: 33
Study 34683948 — intervention group
Group type: EXPERIMENTAL
Intervention: GF:IF = 0.5 with cumulative dose of 1.5 mg salbutamol
Number of subjects: 75
Study 34683948 — intervention group
Group type: COMPARATOR
Intervention: GF:IF = 1.0 with cumulative dose of 1.5 mg salbutamol
Number of subjects: 75
Study 34683948 — intervention group
Group type: COMPARATOR
Intervention: GF = 50 L/min with cumulative dose of 1.5 mg salbutamol
Number of subjects: 75
Study 34683948 — intervention group
Group type: EXPERIMENTAL
Intervention: GF:IF = 0.5 with cumulative dose of 3.5 mg salbutamol
Number of subjects: 75
Study 34683948 — intervention group
Group type: COMPARATOR
Intervention: GF:IF = 1.0 with cumulative dose of 3.5 mg salbutamol
Number of subjects: 75
Study 34683948 — intervention group
Group type: COMPARATOR
Intervention: GF = 50 L/min with cumulative dose of 3.5 mg salbutamol
Number of subjects: 75
Study 35794674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine at a rate of 1 mg/h for the first 6 hours postoperatively, with adjustments based on NRS pain evaluation
Number of subjects: 0
Study 35794674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1 g every 6 hours and ketorolac 30 mg every 8 hours for the first 3 postoperative days
Number of subjects: 0
Study 33386290 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal local treatment for nodal oligorecurrent prostate cancer
Number of subjects: 0
Study 37405698 — intervention group
Group type: EXPERIMENTAL
Intervention: SKILLZ intervention (sport-based, near-peer-led SRH curriculum)
Number of subjects: 2791
Study 37405698 — intervention group
Group type: EXPERIMENTAL
Intervention: SKILLZ intervention (high attendance participants)
Number of subjects: 2791
Study 37405698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2791
Study 32938484 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (ASE formula)
Number of subjects: 95
Study 32938484 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (Th formula)
Number of subjects: 95
Study 32938484 — intervention group
Group type: COMPARATOR
Intervention: CMR (reference method)
Number of subjects: 95
Study 34978530 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-specific virtual reality (ICU-VR)
Number of subjects: 89
Study 34058883 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 151
Study 34058883 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 151
Study 35842821 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable macroporous polysaccharide composites (AMPC)
Number of subjects: 252
Study 35842821 — intervention group
Group type: COMPARATOR
Intervention: Compound microporous polysaccharide hemostatic powder (CMPHP)
Number of subjects: 252
Study 32229495 — intervention group
Group type: EXPERIMENTAL
Intervention: Contezolid (MRX-I) therapeutic dose (800 mg)
Number of subjects: 52
Study 32229495 — intervention group
Group type: EXPERIMENTAL
Intervention: Contezolid (MRX-I) supratherapeutic dose (1,600 mg)
Number of subjects: 52
Study 32229495 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 52
Study 32229495 — intervention group
Group type: EXPERIMENTAL
Intervention: Contezolid (MRX-I)
Number of subjects: 52
Study 34797500 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Wee Method (supra-pubic stimulation with cold saline)
Number of subjects: 140
Study 34797500 — intervention group
Group type: COMPARATOR
Intervention: Usual care (clean catch with no bladder stimulation)
Number of subjects: 140
Study 33845127 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐consult® application
Number of subjects: 0
Study 33845127 — intervention group
Group type: COMPARATOR
Intervention: Consultation without e‐consult®
Number of subjects: 0
Study 35807913 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight‐week interdisciplinary weight loss and lifestyle intervention combined with usual‐care
Number of subjects: 89
Study 35807913 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 89
Study 32507624 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) supplementation (140 mL nitrate-rich BJ concentrate)
Number of subjects: 18
Study 32507624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 32763006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic femoral head (BIOLOX delta)
Number of subjects: 50
Study 32763006 — intervention group
Group type: COMPARATOR
Intervention: Metal femoral head (CoCr)
Number of subjects: 50
Study 36044708 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO: 1 g/kg/h)
Number of subjects: 7
Study 36044708 — intervention group
Group type: COMPARATOR
Intervention: Control (CON: nutrient free)
Number of subjects: 7
Study 36044708 — intervention group
Group type: EXPERIMENTAL
Intervention: Let7i‐5p
Number of subjects: 7
Study 36044708 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐195‐5p
Number of subjects: 7
Study 33705205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib monotherapy (300 mg orally once daily on days 1-5 and 8-12 of a 21-day cycle)
Number of subjects: 34
Study 33705205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib monotherapy
Number of subjects: 34
Study 32075958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis (6.9% THC, 50.6 mg)
Number of subjects: 20
Study 32075958 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cannabis (6.9% THC, 50.6 mg)
Number of subjects: 20
Study 32075958 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (6.9% THC, 50.6 mg)
Number of subjects: 20
Study 32075958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34181037 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-liver transplantation
Number of subjects: 0
Study 34181037 — intervention group
Group type: COMPARATOR
Intervention: Ductal stenting
Number of subjects: 0
Study 34181037 — intervention group
Group type: COMPARATOR
Intervention: Controlled reoxygenation
Number of subjects: 0
Study 34181037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid palliation strategy
Number of subjects: 0
Study 35147645 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 30
Study 35147645 — intervention group
Group type: COMPARATOR
Intervention: Photo-biomodulation (PBM)
Number of subjects: 30
Study 32954832 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure telemonitoring and remote counselling (BPTM)
Number of subjects: 240
Study 32954832 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 240
Study 32542854 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 100
Study 32542854 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 100
Study 34816373 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX03
Number of subjects: 262
Study 34816373 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 262
Study 34143779 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced adherence support with adherence feedback from intracellular tenofovir-diphosphate (TFV-DP) levels in dried blood spots (DBS)
Number of subjects: 451
Study 34143779 — intervention group
Group type: COMPARATOR
Intervention: Standard adherence support (counseling, 2-way SMS, and adherence clubs)
Number of subjects: 451
Study 34143779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Enhanced and Standard adherence support)
Number of subjects: 451
Study 34224478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens with a 7.0 mm optic and plate haptic design (Group 1)
Number of subjects: 120
Study 34224478 — intervention group
Group type: COMPARATOR
Intervention: Intraocular lens with a 6.0 mm optic and C-loop haptic design (Group 2)
Number of subjects: 120
Study 32811186 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 92
Study 32811186 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture (MA)
Number of subjects: 92
Study 34490460 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat follow‐up group
Number of subjects: 168
Study 34490460 — intervention group
Group type: COMPARATOR
Intervention: Outpatient follow‐up group
Number of subjects: 168
Study 32216555 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (20 mg/kg)
Number of subjects: 0
Study 32216555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tylosin (55 mg/kg)
Number of subjects: 0
Study 32216555 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlortetracycline (CTC, 55 mg/kg)
Number of subjects: 0
Study 32216555 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 35641878 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lignocaine infusion (1.5 mg/kg at induction followed by 1.5 mg/kg/h for 1 hour in PACU)
Number of subjects: 70
Study 35641878 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lignocaine infusion
Number of subjects: 70
Study 35641878 — intervention group
Group type: COMPARATOR
Intervention: Normal saline IV infusion
Number of subjects: 70
Study 34058036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised amphotericin B
Number of subjects: 33
Study 34058036 — intervention group
Group type: COMPARATOR
Intervention: Oral itraconazole
Number of subjects: 33